ARCHIVES

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

This article is from The Cancer Letter archive.

Vol. 32 No. 21 | June 2, 2006

Download PDF Visit The Full Archive

Related Articles

DCPC Board Okays Recompetition Of Computer Contract

May 30, 1986

More Cost-Effective To Use Cetuximab In Patients With Wild-Type KRAS Gene

August 28, 2009

Also in this 8-page issue: FDA begins search for director of new Office of Oncology Drug Products.

October 8, 2004

Chi Van Dang Named Director of University Of Pennsylvania Abramson Cancer Center

July 15, 2011

Chart of FY 1991 Budget For NCI By Mechanism

February 2, 1990

Professional Societies: ASCO Develops Cancer Genetics Curriculum

December 18, 1998